A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

JS7 plasmid DNA and MVA62B vaccine

JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)

Trial Locations (3)

30312

AIDS Research Consortium of Atlanta, Atlanta

35294

The University of Alabama at Birmingham Alabama Vaccine Research Clinic, Birmingham

90015

AIDS Research Alliance, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AIDS Research Consortium of Atlanta

OTHER

collaborator

University of Alabama at Birmingham

OTHER

collaborator

AIDS Research Alliance

OTHER

lead

GeoVax, Inc.

INDUSTRY

NCT01378156 - A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART | Biotech Hunter | Biotech Hunter